Repository logo
 

Analysis of ¹³C and ¹⁴C labeling in pyruvate and lactate in tumor and blood of lymphoma-bearing mice injected with ¹³C- and ¹⁴C-labeled pyruvate

Published version
Peer-reviewed

Change log

Authors

Brindle, KM 
Serrao, Eva 
Kettunen, Mikko 
Rodrigues, Tiago 
Lewis, David 

Abstract

Measurements of hyperpolarized ¹³C label exchange between injected [1-¹³C]pyruvate and the endogenous tumor lactate pool can give an apparent first order rate constant for the exchange. Determination of isotope flux, however, requires an estimate of the labeled pyruvate concentration in the tumor. This was achieved here by measuring tumor uptake of [1-¹⁴C]pyruvate, which showed that <2% of the injected pyruvate reached the tumor site. Multiplication of this estimated labeled pyruvate concentration in the tumor with the apparent first order rate constant for hyperpolarized ¹³C label exchange gave an isotope flux that showed good agreement with a flux determined directly by injecting non polarized [3-¹³C]pyruvate and then rapidly excising the tumor after 30 s and measuring ¹³C-labeled lactate concentrations in tumor extracts. The distribution of labeled lactate between intra- and extracellular compartments and the blood pool was investigated by imaging, by measuring labeled lactate concentration in blood and tumor, and by examining the effects of a gadolinium contrast agent and a lactate transport inhibitor on the intensity of the hyperpolarized [1-¹³C]lactate signal. These measurements showed that there was significant export of labeled lactate from the tumor but that labeled lactate in the blood pool produced by injection of hyperpolarized [1-¹³C]pyruvate has only relatively low levels of polarization. This study has shown that measurements of hyperpolarized ¹³C label exchange between pyruvate and lactate in a murine tumor model can provide an estimate of the true isotope flux if the concentration of labeled pyruvate that reaches the tumor can be determined.

Description

Keywords

hyperpolarized ¹³C, lactate, metabolism, pyruvate, tumor

Journal Title

NMR in Biomedicine

Conference Name

Journal ISSN

0952-3480
1099-1492

Volume Title

Publisher

Wiley-Blackwell
Sponsorship
Cancer Research Uk (None)
Cancer Research Uk (None)
Cancer Research Uk (None)
European Commission (264780)
This work was supported by a Cancer Research UK Programme grant (17242) awarded to K.M.B. and the Cancer Research UK & Engineering and Physical Sciences Research Council (CRUK-EPSRC) Imaging Centre in Cambridge and Manchester (16465). E.M.S. is a recipient of a fellowship from the European Union Seventh Framework Programme (FP7/2007-2013) under the Marie Curie Initial Training Network METAFLUX (project number 264780). T.B.R. is a recipient of an Intra-European Marie Curie (FP7-PEOPLE-2009-IEF, Imaging Lymphoma) fellowship and a Long-term European Molecular Biology Organization (EMBO-ALT-1145-2009) fellowship. E.M.S. acknowledges the educational support of the Programme for Advanced Medical Education from the Calouste Gulbenkian Foundation, Champalimaud Foundation, Ministerio de Saude and Fundacao para a Ciencia e Tecnologia, Portugal. The polarizer and related materials were provided by GE Healthcare. The polarimeter was provided by the National Institute for Health Research (NIHR) Cambridge Biomedical Centre. The laboratory is a member of and receives support from the CRUK-EPSRC Cancer Imaging Centre in Cambridge and Manchester. This work was conducted under a research agreement with GE Healthcare. K.M.B. and M.I.K. hold patents with GE Healthcare on some aspects of the polarizer technology.
Relationships
Is supplemented by: